Abstract
Cystic fibrosis (CF) is an inherited monogenic disorder, amenable to gene-based therapies. Because CF lung disease is currently the major cause of mortality and morbidity, and the lung airway is readily accessible to gene delivery, the major CF gene therapy effort at present is directed to the lung. Although airway epithelial cells are renewed slowly, permanent gene correction through gene editing or targeting in airway stem cells is needed to perpetuate the therapeutic effect. Transcription activator-like effector nuclease (TALEN) has been utilized widely for a variety of gene editing applications. The stringent requirement for nuclease binding target sites allows for gene editing with precision. In this study, we engineered helper-dependent adenoviral (HD-Ad) vectors to deliver a pair of TALENs together with donor DNA targeting the human AAVS1 locus. With homology arms of 4 kb in length, we demonstrated precise insertion of either a LacZ reporter gene or a human cystic fibrosis transmembrane conductance regulator (CFTR) minigene (cDNA) into the target site. Using the LacZ reporter, we determined the efficiency of gene integration to be about 5%. In the CFTR vector transduced cells, we were able to detect CFTR mRNA expression using qPCR and function correction using fluorometric image plate reader (FLIPR) and iodide efflux assays. Taken together, these findings suggest a new direction for future in vitro and in vivo studies in CF gene editing.
Highlights
Cystic fibrosis (CF) is an inherited autosomal recessive disease most commonly seen in the Caucasian population [1]
Results showed that Transcription activator-like effector nuclease (TALEN) protein and mRNA expression was undetectable after 5–6 passages (Figure 6B,C, Supplementary Figure S4)
We conclude that the helper-dependent adenoviral (HD-Ad) integration vector did not show prolonged presence of TALEN or vector in transduced cells
Summary
Cystic fibrosis (CF) is an inherited autosomal recessive disease most commonly seen in the Caucasian population [1]. Cystic Fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Cystic Fibrosis affects multiple organs and currently 80% of mortality is caused by lung failure [3]. Conventional treatments including antibiotics, physical therapy, and nutritional supplements can alleviate the symptoms but not provide an effective treatment for the disease. Over the past few years, new treatment strategies have been evolving; different types of CFTR channel modulators have been shown to be effective in improving channel activity in CF patients [4,5,6,7,8,9,10]. While substantial progress has been made in the development of CF therapies, current treatment strategies including the multiple channel modulator/corrector usage impose a heavy drug burden on patients.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
